PPP1R3F Activators
PPP1R3F activators are involved in the modulation of its activity through the influence of intracellular signaling molecules that undergo changes in concentration, subsequently affecting the phosphorylation state of PPP1R3F. These activators function by inducing an increase in cyclic nucleotides, such as cAMP and cGMP, within the cell. The elevation of cAMP is primarily achieved through the direct activation of adenylyl cyclase or the inhibition of phosphodiesterases, which are enzymes responsible for cyclic nucleotide degradation. The resulting higher levels of cAMP activate protein kinase A (PKA), a kinase that can phosphorylate and regulate the activity of various proteins, including PPP1R3F. PKA-mediated phosphorylation of PPP1R3F enhances its regulatory role in glycogen metabolism, directly increasing its functional activity. Similarly, increases in cGMP levels, achieved by inhibiting specific phosphodiesterases, activate protein kinase G (PKG), which can also target PPP1R3F for phosphorylation, thereby modulating its activity.
Aside from the cyclic nucleotide route, some activators exert their influence by targeting other phosphatases that normally decrease the phosphorylation level of proteins. By inhibiting these phosphatases, such as PP1 and PP2A, the activators can indirectly lead to a net increase in protein phosphorylation, including that of PPP1R3F. This mechanism allows for a sustained activation of PPP1R3F by maintaining its phosphorylated state, which is crucial for its role in glycogen synthesis and storage. The phosphorylated form of PPP1R3F is more effective in binding to glycogen and targeting glycogen synthase, the key enzyme in the glycogen biosynthesis pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Elevates intracellular cAMP levels by activating adenylyl cyclase, leading to the activation of protein kinase A (PKA). PKA can phosphorylate and regulate the activity of PPP1R3F, thereby increasing its activity in glycogen metabolism. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, which increase the levels of cAMP and cGMP by preventing their degradation. Higher cAMP levels activate PKA, which in turn can enhance the activity of PPP1R3F. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
A potent inhibitor of protein phosphatases PP1 and PP2A. By inhibiting these phosphatases, okadaic acid can indirectly lead to increased phosphorylation levels of proteins, including PPP1R3F, thus potentially activating its regulatory function. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $160.00 $750.00 | 59 | |
Inhibits PP1 and PP2A like okadaic acid, and could similarly increase the phosphorylation state of PPP1R3F, indirectly enhancing its activity. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
A cell-permeable cAMP analog that directly activates PKA. Activation of PKA can lead to phosphorylation and activation of PPP1R3F. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Phosphodiesterase inhibitor that increases cGMP levels in cells, indirectly leading to activation of protein kinase G (PKG). PKG can phosphorylate PPP1R3F, potentially increasing its activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Selective inhibitor of phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels and subsequent activation of PKA. PKA may then phosphorylate and activate PPP1R3F. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
A PDE1 inhibitor that increases levels of cAMP and cGMP, thus potentially leading to the activation of PKA or PKG, which in turn could phosphorylate and activate PPP1R3F. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $90.00 $350.00 | 16 | |
Inhibits PDE3, increasing cAMP concentration and activating PKA, which could phosphorylate PPP1R3F, leading to its increased activity. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $162.00 $683.00 | 7 | |
A PDE3 inhibitor that increases intracellular cAMP levels, leading to PKA activation. PKA can then increase the activity of PPP1R3F through phosphorylation. | ||||||